INTRODUCTION
Charcot-Marie-Tooth (CMT) and related peripheral neuropathies represent a heterogeneous group of genetic disorders of the peripheral nervous system with an estimated frequency of 1 in 2,500 individuals, making it one of the most common inherited neurological diseases. CMT usually presents clinically as a distal symmetric polyneuropathy. 1 During the past two decades, mutations in >40 genes were found to be causative for CMT; however, the molecular etiology is still not elucidated in ~10-20% of cases.
Copy-number variation (CNV) of the PMP22 gene region, due to the CMT1A duplication that frequently occurs de novo by the mechanism of nonallelic homologous recombination, is the most common underlying etiology; duplication of PMP22 gene region represents 70% of demyelinating, CMT1, neuropathy cases. 2, 3 Furthermore, rare CNVs that occur by mechanisms other than nonallelic homologous recombination and either change PMP22 copy number or disrupt PMP22 function can also be observed in some patients. 4, 5 Deletion CNVs of the X-linked Cx32 (GJB1) gene have also been reported. 6 However, CNVs of other neuropathy genes are rarely reported. 7 In this article, we describe a family with an intragenic duplication CNV in one of the autosomal-recessive (AR)-CMT genes, NDRG1, with three affected individuals born to consanguineous parents from a first-degree cousin marriage. To the best of our knowledge, this is the first report of AR duplication CNV causing a CMT disease phenotype and only the third mutation reported in the NDRG1 gene.
MATERIALS AND METHODS

Patients
This study was approved by the Institutional Review Board of both collaborating institutions, and informed consent was
Original research article obtained before participation in this study. Twelve families with distal symmetric polyneuropathy referred to the Department of Neurology, Istanbul Medical Faculty at Istanbul University were included in this study. Deletion/duplication of the PMP22 gene region, point mutations in PMP22, myelin protein zero (MPZ), GJB1, and MPZ were excluded before the application of CMT gene targeted whole-genome array comparative genomic hybridization (aCGH). In a family in which we detected duplication CNV (HOU 1463), extended clinical studies including hearing tests, ophthalmologic examinations, and brain imaging studies were conducted on both apparently healthy and affected subjects.
CNV analysis
We designed a high-density oligonucleotide-based Agilent 8 × 60K custom microarray for investigating CNVs in CMT gene regions and linkage regions which potentially host CMT genes by using the Agilent eArray website (http://earray.chem. agilent.com/earray). We included 67 genes and their flanking 50 kb of upstream and downstream regions with an average genomic resolution of ~1 probe/200 bp. We also included 10 CMT linkage regions for which the responsible gene has not yet been identified with an average genomic resolution of ~1 probe/5 kb. Experiments were performed according to the manufacturer's protocol and previously described methods. 8 Briefly, parameters for digestion, labeling, purification of the labeled product, hybridization with gender-matched male (NA10851) or female (NA15510) control DNAs (obtained from Coriell Cell Repositories; http://ccr.coriell.org), washing, and scanning were conducted per the manufacturer's protocol (version 6.0). Slides were scanned on Agilent Technologies' DNA Microarray Scanner with a Surescan High-Resolution Technology scanner. Computational analyses including data extraction, background subtraction, and normalization were performed using Agilent Feature Extraction Software 10_7_3_1 (Agilent Technologies, Santa Clara, CA). These data were subsequently imported into aCGH analytics software (Genomic Workbench Standard Edition 5.0.14; Agilent Technologies). The genomic copy number was defined by analysis of the normalized log2 (Cy5/Cy3) ratio average of the CGH signal.
Breakpoint junction analyses
To detect the breakpoint junctions of the duplication, primers were designed at the apparent boundaries of duplication based on aCGH analysis and the genomic coordinates of interrogating probes demarcating transitions from normal copy to apparent copy-number gain consistent with duplication. Primers used for breakpoint junction included: 3724-2F1: 5′-AGGACTGGACAGAGACCTCGACCTT -3′ and 3724-2R1 5′-TGGGGCCGGTATTAGAACCTATGAA -3′. From comparisons with the reference haploid human genome sequence (http:// genome.ucsc.edu/cgi-bin/hgTracks), the duplicated segment was expected to yield a polymerase chain reaction (PCR) product that is small enough (~12.5 kb) to be amplified by long-range PCR. We therefore performed long-range PCR to amplify the entire duplicated segment using primers flanking this region-3724-F1: 5′-CTGGAGCAGTAAGAAGCAAGGACGA-3′ and 3724-R1: 5′-GGATGCGAAGGGACTAGACTTGGG-3′-that amplify an ~14.8 kb segment encompassing the duplication and an ~7.4 kb segment in a wt allele. Experiments were performed as previously described.
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Quantitative real-time reverse transcriptase-PCR
To study the mRNA expression of the NDRG1 gene, we performed quantitative real-time reverse transcriptase-PCR in homozygous/heterozygous duplicated and wild-type individuals from the family. Total RNA was prepared from blood by using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA), and cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad Hercules, CA). The real-time PCR assay was conducted with the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) using TaqMan Fast universal PCR master mix (Applied Biosystems). The cDNA samples were subsequently analyzed as triplicates by quantitative RT-PCR using TaqMan Gene Expression Assay (NDRG1: Hs 00608387_ m1, Applied Biosystems) and Pre-Developed TaqMan Assay Reagents for TBP (Applied Biosystems) as a control gene. Experiments were carried out according to the manufacturer's protocol. Relative fold of mRNA expression changes were calculated using the comparative threshold cycle method (ΔΔCT).
Genome-wide SNP array genotyping
To investigate whether there are any other large CNVs in the genome and/or regions of homozygosity that may contribute to the phenotype, we performed genome-wide single-nucleotide polymorphism (SNP) array genotyping in all the members of this family using the Illumina OmniExpress Beadchip (Illumina, San Diego, CA) that interrogates 730,525 markers across the genome. Analysis of the SNP array data was performed using the Illumina Genome Studio software (Illumina).
RESULTS
Clinical evaluation
The proband (BAB3724 = II-2) was a 30-year-old male who had delayed motor milestones. Gait disturbance and frequent falls were first noted at 3 years of age. Involvement of the upper limbs became apparent at the age of 10 years. Orthopedic correction (achilloplasty) of both feet was carried out at 12 years of age. He also had hearing loss, which was noted at ~4 years of age. All neurological symptoms and signs were progressive.
The physical examination revealed severe distal and mild proximal muscle weakness and distal wasting with areflexia. Light touch, vibration, and position senses were severely diminished distally. Severe deformities including kyphoscoliosis, pes cavus, hammer toes, and claw hands were observed. Nerve conduction studies showed the absence of sensory nerve action potentials in all limbs ( Table 1) . Compound motor nerve potentials (CMAPs) could not be obtained. Musculocutaneous nerve (recorded from biceps muscle) motor conduction study revealed low CMAP amplitudes whereas axillary CMAPs (recorded from deltoid muscle) were normal. Brain magnetic resonance imaging was normal. Audiometry showed moderate sensorineural hearing loss especially at low frequencies. Detailed ocular examination raised suspicion of glaucoma. Intraocular pressure was normal with normal visual fields and so was the gonioscopic examination. Optical coherence tomography showed that the right retinal nerve fiber layer had a borderline thickness.
The proband's affected 26-year-old sister (BAB4148 = II-3) was not examined however, she was said to have delayed motor milestones and deafness noted at the age of 2 years. She also had pes cavus, hammer toes, and claw hands. Audiometric tests revealed sensorineural hearing loss at both low and high frequencies.
The 24-year-old sister (BAB4149 = II-4) was more seriously affected than her siblings. She walked at the age of 1 year but had an unsteady gait. At the age of 5 years, weakness in her hands became apparent. She underwent orthopedic surgery (achilloplasty) at the age of 6 years. At the age of 18 years, she was diagnosed with glaucoma and myopia. She also had bilateral deafness. Symptoms progressed rapidly, and she was unable to walk without support in her teens. Her clinical examination showed severe distal and moderate proximal muscle weakness. All tendon reflexes were absent. Light touch, vibration, and position senses were severely diminished in the distal portions of her limbs. She had pes cavus, hammer toes, and claw hands.
Sensory nerve action potentials were absent in both upper and lower limbs ( Table 1) . CMAPs recorded from distal muscles were also absent. The amplitudes of musculocutaneous (biceps) and axillary CMAPs (deltoid) were reduced. Needle electromyography showed no activity in distal and proximal muscles of the lower limbs and distal muscles of the upper limbs; chronic denervation findings were present in proximal muscles of the upper limbs. Brain magnetic resonance imaging was normal. Audiometry tests could not be performed in this subject.
Healthy individuals BAB4150 (II-5) and BAB4151 (II-6) could not be examined, but they were reported to be normal. The clinical examination and motor and sensory nerve conduction studies were unremarkable (Table 1) in the other male healthy sibling BAB5658: II-1. His ocular examination and audiometry test were normal.
Subject BAB4152 (II-7) has a different clinical picture from other affected individuals in this family; in particular, this subject has a distinct neurological phenotype. She was born with pes equino varus deformity. She underwent orthopedic correction at the age of 1 and 3 years. Motor milestones were delayed, and she could never walk normally. Her hands were weak since early childhood. But unlike the others, the disease was slowly progressive. She did not complain of hearing or vision problems. She was treated for generalized tonic-clonic seizures since the age of 6 years. Her clinical examination revealed severe distal and moderate proximal muscle weakness in the lower limbs and moderate distal muscle weakness in the upper limbs. All tendon reflexes were present except at the achilles tendon. Vibration sensation was mildly diminished distally. 
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She had mild-to-moderate intellectual disability, difficulty in performing daily activities, slurred speech, and difficulty in understanding commands. Furthermore, she was unable to complete elementary school due to consecutive failures in the first grade. Sensory nerve action potentials and sensory conduction velocities were normal in all limbs ( Table 1) . Peroneal CMAPs (recorded from extensor digitorum brevis and tibialis anterior muscles) were absent, tibial CMAP amplitudes were reduced and tibial motor conduction velocities were normal. In the upper limbs, CMAP amplitudes and motor conduction velocities were within the normal limits. Needle electromyography showed that the chronic neurogenic changes were prominent in distal muscles of the lower limbs. Brain magnetic resonance imaging was normal. Detailed ocular examination showed a high suspicion of glaucoma. Intraocular pressure was normal with normal visual fields and normal gonioscopic examination for both eyes. Optical coherence tomography exposed generalized thinning in both retinal nerve fiber layer. Audiometry test was within the normal range.
NDRG1 intragenic CNV
We designed a targeted aCGH platform to investigate all known CMT gene regions of the human genome for CNV as small as <1 kb in length. We detected an apparent ~6.25 kb region of increased copy number (chr8: 134265065-134271319) encompassing exons 6-8 of the NDRG1 gene in the index case who presented with distal symmetric polyneuropathy and was given a diagnosis of CMT (BAB3724 = II-2); however, the observed aCGH gain (0.63-0.76) in affected individuals was more consistent with four copies of the locus, potentially reflecting either homozygous duplication or triplication. An extended family study showed that both unaffected parents and presumed heterozygous siblings have an intermediate copy number of NDRG1 with an average probe intensity of 0.37 (0.33-0.43) consistent with three copies at the locus. Affected siblings carry the same CNV gain as the index case level, with an average probe intensity of 0.71 (0.63-0.76), and unaffected siblings have an apparent normal copy number with an average probe intensity of 0.025 (0.00-0.05) (Figure 1a) . These family segregation studies support the notion that a homozygous duplication is associated with the known NDRG1 mutation-associated neuropathy, whereas heterozygous duplication represents a carrier state for this recessive trait (Figure 1a) , a contention further supported by follow-up PCR studies (see below). Breakpoint junction analysis revealed that five base pairs (AGTGG) of microhomology was shared between proximal and distal reference sequences: the proximal breakpoint mapped within a 229 bp short local repeat. Breakpoint junction studies showed that individuals, who carry the duplication in either the homozygous or heterozygous state, have a 1 kb junction amplification product. As anticipated, individuals who have normal alleles do not show any PCR junction band, consistent with the array results and the Mendelian expectation for a recessive model of inheritance (Figure 2a-c) .
To be able to amplify the entire duplicated segment, oppositely oriented primers flanking the apparent duplication CNV were designed for a long-range PCR assay. The flanking primers amplify an ~14.8 kb band encompassing the ~12.5 kb duplicated region delineated from aCGH, therefore both array and breakpoint junction PCR results support the duplication event.
We observed a single 14.8 kb PCR band in suspected homozygous duplicated individuals, two PCR bands of 7.4 and 14.8 kb in heterozygous individuals, and a single 7.4 kb PCR band in normal or wild-type individuals (Figure 2a,b) . These studies clearly demonstrate a duplication structure and homozygous duplication, not triplication, in affected CMT individuals in this family. In addition, breakpoint PCR only generated 1 kb amplicons in individuals with suspected heterozygous or homozygous duplication (Figure 2c) . 
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To assess how this intragenic genomic CNV affected gene function, after reverse transcriptase-PCR we performed cDNA sequencing of lymphoblastoid cell line RNA from both affected and unaffected individuals. As predicted by conceptual translation and shown by RT-PCR, we observed that the duplication of exon 6-8 in affected individuals leads to a nonsense mutation at codon 223 in the mRNA (Figure 3a,b) .
We compared the expression levels of NDRG1 in two individuals with homozygous duplication (BAB3724 and BAB4149), heterozygous duplication (BAB4146 and BAB4147), and wild type (BAB4150 and BAB4152) by using TaqMan Q-PCR. We observed a decrease of 0.12-fold (BAB3724) and 0.18-fold (BAB4149) in homozygous duplication individuals and 0.61-fold (BAB4146) and 0.6-fold (BAB4147) in unaffected heterozygous duplication individuals compared with a healthy family member (P < 0.001) (Figure 3c) .
Regions of homozygosity and other potential CNVs
We performed whole-genome SNP arrays on DNA samples from all available family members to assess the genome-wide extent of absence of heterozygosity (AOH) including the precise region and size of AOH encompassing NDRG1. We then determined whether there are other CNVs in the genome that could potentially contribute to the phenotype in the family or perhaps explain the clinical variability of affected family members. We did not observe any additional large CNV detected by SNP array elsewhere in the genome or in other CMT gene regions or elsewhere that segregates with the CMT phenotype investigated in this report, nor did we identify any large de novo CNV that might explain the intellectual disability in family member II-7.
As expected due to the consanguinity in the family, the proband and other siblings have several regions of homozygosity, or AOH, throughout their genome. In total, 33 AOH regions spanning from 1.0 to 44.3 Mb in size were identified in the proband. The NDRG1 gene is encompassed within the largest 44.3 Mb region of AOH in this individual; and comparing multiple affected individuals, the minimum region of overlap between AOH regions spanning NDRG1 is 21.9 Mb (Figure 4) .
DISCUSSION
In this article, we report the first AR duplication CNV of NDRG1 causing hereditary motor and sensory neuropathyLom (HMSN-Lom)/CMT4D (MIM: 601455) in a large Turkish pedigree. AR-CMT accounts for only 4% of the families in the European CMT population. 9, 10 By contrast, in communities with a higher rate of consanguineous marriage, for example, Middle Eastern countries, AR-CMT accounts for ~30-50% of all CMT cases. 10, 11 Approximately one-half of all patients with CMT 12 and 70% of all patients with the demyelinating type (CMT1) have a 1.4 Mb duplication as the cause of their disease. [13] [14] [15] In addition, rare smaller sized CNVs involving PMP22 have also been reported. 5 However, CNVs in non-CMT1A patients are rarely reported. Hoyer et al. 16 and Maeda et al. 17 reported dominant CNVs in the gene encoding MPZ. In the X-linked recessive form of CMT, whole-gene deletions of GJB1 have been reported. 6, 17 Huang et al. screened 97 CMT patients for CNVs, and detected a novel shorter form of PMP22 duplication and two other CNVs in MTMR2 (CMT4B1, MIM: 603557) and ARHGEF10 (autosomal-dominant slowed nerve conduction velocity, MIM: 608136), which were determined to be non-disease-causing variants.
In the NDRG1 intragenic CNV reported in this article, breakpoint junction analysis reveals a 5 bp microhomology at the breakpoint, supporting a replicative mechanism such as fork stalling and template switching/microhomology-mediated breakage-induced replication as the underlying mechanism Sanger sequence results of cDNA from the control and affected individuals. In healthy individuals, exon 8 is followed by exon 9 and in affected individuals exon 8 is followed by exon 6. (b) Analysis of the resultant sequence at the amino acid level. The duplication causes a frame shift mutation, altering the amino acid sequence for several residues before a premature termination codon. (c) Expression levels in blood were measured by quantitative RT-PCR using the TaqMan gene expression assay in triplicate and normalized to TBP. We observed a decrease in expression, 0.12-to 0.18-fold in patient samples (BAB3724 and BAB4149) and 0.6-to 0.61-fold in carriers (BAB4146 and BAB4147), compared with normal expression controls. We found an obviously decreased expression in both patients and carriers compared with control healthy individuals. *P < 0.01. Original research article for generation. 4 This is different from nonallelic homologous recombination, the underlying mechanism for 1.4 Mb recurrent duplication of PMP22 in CMT1A patients. Breakpoint junctions were studied in detail in GJB1 deletion and MPZ duplication cases also. 6, 17 In other CMT families that are caused by CNV, Alu-mediated deletion in GJB1 and duplication in MPZ have been observed, as well as microhomology-mediated deletion in GJB1. These data show that mechanisms other than nonallelic homologous recombination can be responsible for the formation of CNVs in non-PMP22 duplication patients.
HMSN-Lom/CMT4D was initially described by Kalaydjieva et al. 18 as an AR peripheral neuropathy with normal intellect, deafness, and unusual neuropathologic features. It was identified in 14 affected individuals from the Gypsy community of Lom, a small town on the Danube River in the northwest of Bulgaria and referred to as "hereditary motor and sensory neuropathy-Lom" (HMSN-Lom). The disorder was subsequently reported in families from Italy, Slovenia, Germany, Spain, France, and Romania. [19] [20] [21] [22] To date, two disease-causing mutations in NDRG1 have been reported in humans: R148X and IVS8-1 G>A (g.2290787G>A) (http://www.molgen.ua.ac. be/CMTMutations/). In addition, a 10 bp deletion leading to a frameshift (p.R361SerfsX60) and a single-nucleotide variant mutation (causing aa change p.G98V) have been described in both inbred Greyhound and Alaskan Malamute pedigrees with polyneuropathy. 23, 24 AR peripheral neuropathies are relatively rare, but can be clinically more severe than autosomal-dominant forms of CMT. Clinically, HMSN-Lom/CMT4D presents with muscle weakness and wasting, tendon areflexia, skeletal and foot deformities, and sensory loss affecting all modalities. Deafness is an invariant feature of the phenotype and usually develops in the third decade. 19, 20, 22, 25, 26 The subjects reported herein showed typical features, including muscle weakness and wasting, tendon areflexia, skeletal and foot deformities, and sensorineural loss with deafness.
The index case of this family (BAB3724) had additional clinical findings suggestive of possible glaucoma. Glaucoma with CMT is a rare feature and was reported in CMT4B2 caused by mutations of SBF2/MTMR13 (MIM: 607697). [27] [28] [29] We initially considered the possibility that glaucoma may be another clinical finding in addition to the peripheral neuropathy and hearing loss in NDRG1 mutation cases. We performed eye examinations in BAB4152 and found that this individual, who has normal copy number in NDRG1, also has glaucoma findings. We then checked an AR glaucoma locus (MIM: 601771) for a possible AOH region spanning the CYP1B1 gene and found no large region of AOH. Improper segregation of NDRG1 and lack of AOH within the AR glaucoma region suggest that glaucoma may be associated with another currently undefined locus in this family. Individual BAB4152 has a history of epilepsy and intellectual disability in addition to a more severe neuropathy than her siblings. The patient is homozygous wild type at the NDRG1 locus, lacks a region of AOH spanning this gene, has a normal level of NDRG1 expression, and has additional clinical features (Figures 2 and 4) . Therefore, we suggest this individual has a different clinical entity than that which we observe in BAB3724, BAB4148, or BAB4149.
Homozygous rare variants (either single-nucleotide variant or small CNV) within regions of AOH may account for variability in the clinical presentation and other features in the differentially affected individuals, such as the glaucoma present in the proband but not in other affected individuals or the intellectual disability and more severe neurological disorder of II-7/BAB4152. However, this hypothesis requires additional analyses and testing, as well as potentially exome sequencing of the differentially affected sibling. Of note, no further large CNVs in CMT gene loci were detected by SNP genotyping, indicating the effectiveness of our targeted array platform.
In this article, we reported the first recessive duplication CNV causing CMT and the third mutation in the NDRG1 gene. Although affected individuals primarily present with features explained by the AR duplication of NDRG1, further findings and clinical variability within the family may potentially be explained by de novo mutations or additional rare variant alleles that arose in recent ancestors and became reduced to homozygosity-a concept embodied in the term "clan genomics. " 30 
